Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI.
Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI:Effects on Oxidative Stress and Inflammation.
Sponsor: GlaxoSmithKline
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from GlaxoSmithKline
Other Diabetes Mellitus, Type 2 trials with similar outcome
Listed as NCT00430040, this PHASE4 trial focuses on Diabetes Mellitus, Type 2 and Hypertension and remains terminated or withdrawn. Sponsored by GlaxoSmithKline, it has been updated 8 times since 2007, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
May 2024 — Jul 2024 [monthly]
Terminated PHASE4
-
Apr 2022 — May 2024 [monthly]
Terminated PHASE4
Status: Unknown Status → Terminated
-
Jan 2021 — Apr 2022 [monthly]
Unknown Status PHASE4
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Unknown Status PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE4
First recorded
Feb 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
- University at Buffalo
For direct contact, visit the study record on ClinicalTrials.gov .